Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-12-05
2006-12-05
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S340000, C514S361000, C546S268700, C546S269100, C548S127000, C548S131000, C548S134000
Reexamination Certificate
active
07144899
ABSTRACT:
Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure Formula (I): wherein u is CH or N; Q is 1)—N(R25)CH(R30)— wherein the nitrogen atom is attached to R1, and R25and R30are independently selected from the group consisting of hydrogen, C3-6cycloalkyl, and C1-6alkyl, or 2) wherein the nitrogen atom is attached to R1, and m is 0, 1, or 2
REFERENCES:
patent: 2277409 (1942-03-01), Murray
patent: 4346078 (1982-08-01), Bajusz et al.
patent: 4703036 (1987-10-01), Bajusz et al.
patent: 4804743 (1989-02-01), Kaltenbronn et al.
patent: 5252566 (1993-10-01), Shuman
patent: 5332726 (1994-07-01), Klein et al.
patent: 5380713 (1995-01-01), Balasubramanian et al.
patent: 5416093 (1995-05-01), Shuman
patent: 5510369 (1996-04-01), Lumma et al.
patent: 5691356 (1997-11-01), Das et al.
patent: 5792779 (1998-08-01), Sanderson et al.
patent: 5798377 (1998-08-01), Lumma et al.
patent: 5866573 (1999-02-01), Sanderson et al.
patent: 5869487 (1999-02-01), Coburn et al.
patent: 6004976 (1999-12-01), Coburn
patent: 6011038 (2000-01-01), Dorsey et al.
patent: 6017934 (2000-01-01), Sanderson et al.
patent: 6051568 (2000-04-01), Gustafsson et al.
patent: 6087373 (2000-07-01), Coburn et al.
patent: 6147078 (2000-11-01), Sanderson et al.
patent: 6239132 (2001-05-01), Coburn et al.
patent: 6515011 (2003-02-01), Selnick et al.
patent: 0 185 210 (1986-06-01), None
patent: 0185210 (1986-06-01), None
patent: 0 195 212 (1986-09-01), None
patent: 0 363 284 (1990-04-01), None
patent: 0 471 651 (1992-02-01), None
patent: 0 479 489 (1992-04-01), None
patent: 0 601 459 (1994-06-01), None
patent: 603112 (1994-06-01), None
patent: 0 648 780 (1995-04-01), None
patent: 0 672 658 (1995-09-01), None
patent: WO 92/07869 (1992-05-01), None
patent: WO 92/14750 (1992-09-01), None
patent: WO 94/29336 (1994-12-01), None
patent: WO 96/31504 (1996-10-01), None
patent: WO 96/32110 (1996-10-01), None
patent: WO 97/15190 (1997-05-01), None
patent: WO 99/29664 (1999-06-01), None
patent: WO 00/35869 (2000-06-01), None
patent: WO 00/75134 (2000-12-01), None
patent: WO 0138323 (2001-05-01), None
patent: WO 02/09711 (2002-02-01), None
D. B. Henriksen et al., “Peptide Amidation by Enzymatic Transacylation and Photolysis”, 1993, vol. 41, pp. 169-180, Int. J. Peptide Protein Res.
S. Bajusz et al., “Highly Active and Selective Anticoagulants: D-Phe-Pro-ARg-H, a Free Tripeptide Aldehyde Prone to Spontaneous Inactivation, and It's Stable N-Methyl Derivative, D-MePhe-Pro-Arg-H”, 1990, vol. 33, pp. 1729-1735, J. Med. Chem.
M. C. Berndt et al., “Platelet Membrane Proteins: Composition and Receptor Function”, 1981, pp. 43-75, Gordon (ed) Platelets in Biology and Pathology-2.
B. M. Martin et al., “Platelet Stimulation by Thrombin and Other Proteases”, 1975, vol. 14, No. 6, pp. 1308-1314, Biochemistry.
N. J. Greco et al., “PPPACK-Thrombin Inhibits Thrombin-Induced Platelet Aggregation and Cytoplasmic Acidifcation but does not Inhibit Platelet Shape Change”, 1990, vol. 75, No. 10, pp. 1983-1990, Blood.
w. Bode et al., “The Refined 1.9 a Crystal Structure of Human alpha Thrombin: Interaction with D-Phe-Pro-Arg Chloromethylketone and Significance of the Tyr-Pro-Pro-Trp Insertion Segment”, 1989, vol. 8, No. 11, pp. 3467-3475, The EMBO Journal.
E. F. Workman et al., “Structure-Function Relationships in the Interaction of the alpha-Thrombin with Blood Platelets”, 1992, vol. 252, No. 20, pp.-7718-7123, The J. of Biol. Chemistry.
K. Y. Hui et al., “Minimal Sequence Requirement of Thrombin Receptor Agonist Peptide”, 1992, vol. 184, No. 2, pp. 790-796, Biolchemical and Biophysical Research Communications.
R. M. Scarborough et al., “Tethered Ligand Agonist Peptides-Structural Requirements for Thrombin Receoptor Activation Reveal Mechanism of Proteolytic Unmasking of Agonist Function”, 1992, vol. 267, No. 19, pp. 13146-13149, J. of Biol. Chemistry.
R. R. Vassallo, Jr. et al., “Structure-Function Relationships in the Activation of Platelet Thrombin Receptors by Receptor-Derived Peptides”, 1992, vol. 267, No. 9, pp. 6081-6085, J. of Biol. Chemistry.
E. J. Iwanowicz et al., “Alpha-Hydroxy-and Alpha Ketoester Functionalized Thrombin Inhibitors”, 1992, vol. 21 No. 12, pp. 1607-1612, Organic and Medicinal Chemistry Letters.
T. Okumura et al., “Platelet Glycocalicin-Interaction with Thrombin and Role as Thrombin Receptor of the Platelet Surface”, 1978, vol. 263, No. 10, pp. 3435-3443, J. of Biol. Chemistry.
D. M. Tollefsen et al., “The binding of Thrombin to the Surface of Human Platelets”, 1974, vol. 249, No. 8, pp. 2646-2651, J. of Biol. Chemistry.
Vu et al., “Molecular Cloning of a Functional Thrombin Receptor Reveals a Novel Proteolytic Mechanism of Receptor Activation”, 1991, vol. 64, pp. 1057-1068, Cell.
R. S. Gronke et al., “Thrombin Interaction with Platelets-Influence of a Platelet Protease Nexin”, 1987, vol. 262, No. 7, pp. 3030-3036, J. of Biological Chemistry.
Phillips, “Thrombin Interaction with Human Platelets Potentiation of Thrombin-Induced Aggregation and Release by Inactivated Thrombin”, 1974, vol. 32, pp. 207-215, Thrombos, Diathes, Haemorrh (Stuttg).
N. Balasubramanian et al., “Active Site-Directed Synthetic Thrombin Inhibitors: Synthesis, in Vitro and in Vivo Activity Profile of BMY 44621 and Analogs. An Examination of the Role of the Amino Group in the D-Phe-Pro-Arg-H Series”, 1993, vol. 36, pp. 300-303, J. Med. Chem.
C. Kettner et al., “The Selective Inhibition of Thrombin by Peptides of Boroarginine”, 1990, vol. 265, No. 30, pp. 18289-18297, J. of Biological Chemistry.
R. T. Shuman et al., “Highly Selective Tripeptide Thrombin Inhibitors”, 1993, vol. 36, No. 3, pp. 314-319, J. of Medicinal Chem.
M. A. Hussian et al., “Anticoagulant Activity of a Peptide Boronic Acid Thrombin Inhibitor by Various Routes of Administration in Rats”, 1991, vol. 12, pp. 1153-1154, Peptides.
C. F. Vencill et al., 1986, vol. 103, Abstract No. 189000 Chemical Abstract.
P. D. Edwards et al., “Design, Synthesis, and Kinetic Evaluation of a Unique Class of Elastase Inhibitors, the Peptidyl alpha-ketobenzoxazoles, and the X-ray Crystal Structure of the Covalent Complex between Porcine Pancreatic Elastase and Ac-Ala-Pro-Val-2-Benzoxazole”, 1992, vol. 114, pp. 1854-1863, J. Am. Chem. Soc.
D. Banner et al., “Serine Proteases: 3D Structures, Mechanisms of Action and Inhibitors”, 1993, pp. 29-43, Chapter 3,Persepct. Med. Chem..
C. Tapparelli et al., “Synthetic Low-Molecular Weight Thrombin Inhibitors: Molecular Design and Pharmacological Profile”, 1993, vol. 14, pp. 366-376, TIPS.
Barrow James C.
Lyle Terry A.
Nantermet Philippe G.
Sanderson Philip E.
Selnick Harold G.
Camara Valerie J.
Coppins Janet L.
Merck & Co. , Inc.
Parr Richard S.
Saeed Kamal A.
LandOfFree
Thrombin inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thrombin inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thrombin inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3710840